Inari Medical
9272 Jeronimo Rd. Suite 124
Irvine
California
92618
United States
Tel: 949-600-8433
Website: http://inarimedical.com/
84 articles with Inari Medical
-
FLAME Study Demonstrates 90% Survival Improvement in High-Risk Pulmonary Embolism with Inari Medical FlowTriever System
3/6/2023
Inari Medical, Inc. announced positive results from the FLAME study in high-risk/massive pulmonary embolism.
-
Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results
2/27/2023
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2022.
-
Inari Medical to Announce Fourth Quarter and Full Year 2022 Financial Results
2/7/2023
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023.
-
Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
1/31/2023
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14, 2023.
-
Inari Medical Announces First Patient Enrolled in the DEFIANCE Trial, Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis
1/12/2023
Inari Medical, Inc. today announced that the first patient has been enrolled in DEFIANCE, a prospective randomized controlled trial (“RCT”) comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis (“DVT”) treated with the ClotTriever System versus anticoagulation only.
-
Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance
1/10/2023
Inari Medical, Inc. today announced preliminary unaudited fourth quarter and full year 2022 revenue and provided estimates for its 2023 guidance.
-
Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/21/2022
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 2:15PM Pacific Time.
-
Inari Medical to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
11/3/2022
Inari Medical, Inc. announced that its management team will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum at the Westin NY Grand Central Hotel in New York on Thursday, November 17, 2022.
-
Inari Medical Reports Third Quarter 2022 Financial Results
11/2/2022
Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, reported financial results for its third quarter ended September 30, 2022.
-
Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT
10/31/2022
Inari Medical, Inc. a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry.
-
Inari Medical to Announce Third Quarter 2022 Financial Results
10/6/2022
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022.
-
Inari Medical to Host First Analyst & Investor Day
9/2/2022
Inari Medical, Inc. announced that its management team will host the Company’s first Analyst and Investor Day on Thursday, September 15, 2022 at its headquarters in Irvine, CA.
-
Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences
9/1/2022
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), announced three new data sets will be presented during Late-Breaking Clinical Trial sessions at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) and the 2022 VEINS (Venous Endovascular Interventional Strategies) conferences.
-
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis
8/30/2022
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the DEFIANCE trial.
-
Inari Medical to Present at Upcoming Investor Conferences in September 2022
8/25/2022
Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced that its management team will present at the following investor conferences.
-
Inari Medical Reports Second Quarter 2022 Financial Results
8/3/2022
Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, reported financial results for its second quarter ended June 30, 2022.
-
Inari Medical Announces Leadership Succession Plan
8/3/2022
Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced that Chief Operating Officer Drew Hykes will succeed Bill Hoffman as Chief Executive Officer, effective January 1, 2023.
-
Inari Medical to Announce Second Quarter 2022 Financial Results
7/18/2022
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022.
-
Inari Medical Reports First Quarter 2022 Financial Results
5/4/2022
Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, reported financial results for its first quarter ended March 31, 2022.
-
Inari Medical to Present at the Bank of America 2022 Healthcare Conference
4/28/2022
Inari Medical, Inc. announced that its management team will present at the Bank of America 2022 Healthcare Conference on Thursday, May 12, 2022 at 10:40 a.m. Pacific Time at the Encore Hotel in Las Vegas.